ADMA · XBRL financial data

Adma Biologics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ADMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	42,220	—	—	—	—	—
Revenue from contracts with customers	42,220	80,943	154,080	258,215	426,454	510,173
Cost of revenue	61,291	79,769	118,815	169,273	206,901	217,408
Gross profit	(19,072)	1,173	35,265	88,942	219,553	292,765
Research and development	5,907	3,646	3,614	3,300	1,813	4,762
Selling, general and administrative	35,051	42,897	52,458	59,020	74,124	91,580
General and administrative	35,051	—	—	—	—	—
Total operating expenses	107,135	59,547	74,630	67,310	80,570	101,322
Operating income (loss)	(64,915)	(58,374)	(39,365)	21,632	138,983	191,443
Interest income	288	35	45	1,617	2,097	1,871
Interest expense	11,985	13,057	19,279	25,027	13,930	7,110
Other income (expense)	(129)	(252)	(634)	(287)	(193)	(212)
Income tax expense (benefit)	0	0	0	0	(71,959)	35,726
Net income (loss)	(75,749)	(71,648)	(65,904)	(28,239)	197,673	146,930
Earnings per share, basic USD per share	(0.88)	(0.51)	(0.33)	(0.13)	0.85	0.62
Earnings per share, diluted USD per share	(0.88)	(0.51)	(0.33)	(0.13)	0.81	0.60
Weighted average shares, basic thousands of shares	86,145	139,579	197,875	223,977	233,084	238,299
Weighted average shares, diluted thousands of shares	86,145	139,579	197,875	223,977	243,342	244,905

Fiscal years (ADMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	55,921	51,089	86,522	51,352	103,147	87,630
Accounts receivable	13,237	28,577	15,505	27,421	49,999	158,429
Inventory	81,536	124,724	163,280	172,906	170,235	206,465
Prepaid and other current assets	3,046	4,339	5,095	5,334	8,029	7,458
Total current assets	153,741	208,729	270,402	257,013	331,410	466,512
Property and equipment, net	41,593	50,935	58,261	53,835	54,707	65,057
Right-of-use asset	4,259	7,263	10,485	9,635	8,634	6,650
Goodwill	3,530	3,530	3,530	3,530	3,530	3,530
Total assets	207,673	276,253	348,462	329,182	488,678	624,242
Accounts payable	11,074	12,429	13,229	15,660	20,219	22,519
Accrued liabilities	8,365	—	—	—	—	—
Current portion of long-term debt	—	—	—	—	0	2,813
Total current liabilities	19,947	30,378	39,267	49,806	55,542	69,541
Long-term debt	—	—	—	—	72,337	69,330
Lease liability, non-current	4,334	7,462	10,704	9,779	8,561	6,646
Total liabilities	119,424	135,080	196,488	193,976	139,660	146,922
Accumulated deficit	(340,465)	(412,113)	(478,017)	(506,256)	(308,583)	(161,653)
Total stockholders' equity	88,249	141,173	151,974	135,206	349,018	477,320
Total liabilities and equity	207,673	276,253	348,462	329,182	488,678	624,242
Common shares outstanding (cover page) thousands of shares	121,275	195,920	222,156	228,220	237,615	238,159

Fiscal years (ADMA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(75,749)	(71,648)	(65,904)	(28,239)	197,673	146,930
Stock-based compensation	2,855	3,488	5,215	6,187	13,616	20,026
Depreciation and amortization	3,200	4,800	6,400	7,600	7,700	8,000
Net cash from operating activities	(102,003)	(112,369)	(59,508)	8,800	118,672	50,396
Purchases of property and equipment	12,727	13,511	13,911	4,771	8,226	22,575
Net cash from investing activities	(12,725)	(13,511)	(13,911)	(4,981)	(8,575)	(21,891)
Proceeds from issuing common stock	131,195	121,144	64,645	0	0	—
Share repurchases	—	—	—	0	0	31,940
Proceeds from long-term debt	27,500	—	—	—	—	—
Repayments of long-term debt	13,950	—	—	—	—	—
Net cash from financing activities	143,897	121,048	108,852	(38,989)	(58,302)	(44,022)
Net change in cash	29,169	(4,832)	35,432	(35,170)	51,795	(15,517)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Adma Biologics	136,020	124,395	29,539*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593,298	388,180	92,203*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133,026	not reported	25,980	52.1M	—	Q1 FY26 10-QMar 31, 2026
Axsome Therapeutics	313,859	259,691	(9,469)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163,138	480,999	240,891*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631,314	480,132	93,477*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	39,981	92,128	(3,062)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183,190	not reported	(232,471)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
PERRIGO	399,700	1,022,800	82,600*	138.8M	—	Q2 FY26 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.